Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Ich bin damit einverstanden, dass mir die BurdaForward GmbH, St. Martin Straße 66, 81541 München, regelmäßig News zu den oben ausgewählten Themenbereichen per E-Mail zusendet. Ich bin ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.